NMRA
NASDAQ · Pharmaceuticals
Neumora Therapeutics Inc
$1.51
-0.02 (-1.31%)
Open$1.58
Previous Close$1.53
Day High$1.63
Day Low$1.43
52W High$3.65
52W Low$0.72
Volume—
Avg Volume5.86M
Market Cap279.78M
P/E Ratio—
EPS$-1.33
SectorPharmaceuticals
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,048.3% upside
Current
$1.51
$1.51
Target
$17.34
$17.34
$11.85
$17.34 avg
$21.76
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 131.86M | 126.94M | 118.45M |
| Net Income | 20.35M | 17.55M | 19.05M |
| Profit Margin | 15.4% | 13.8% | 16.1% |
| EBITDA | 29.65M | 29.50M | 31.41M |
| Free Cash Flow | 15.46M | 12.66M | 10.19M |
| Rev Growth | -7.9% | +5.6% | -2.9% |
| Debt/Equity | 0.29 | 0.31 | 0.30 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,107.08 | +0.45% | 40.9 | 1.03T |
| JNJ | Johnson & Johnson | $239.08 | +3.37% | 26.1 | 549.78B |
| MRK | Merck & Co. Inc. | $119.60 | +3.57% | 31.5 | 281.24B |
| PFE | Pfizer Inc. | $24.72 | -1.44% | 19.2 | 143.68B |
| BMY | Bristol-Myers Squibb Co | $55.53 | +1.52% | 18.5 | 110.27B |
| ZTS | Zoetis Inc | $76.84 | +1.25% | 12.5 | 33.00B |